Renalytix Plc
RNLX · NASDAQ
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | |
|---|---|---|---|---|
| Revenue | $2 | $3 | $3 | $1 |
| % Growth | -32.7% | 14.6% | 99.2% | – |
| Cost of Goods Sold | $2 | $3 | $2 | $1 |
| Gross Profit | $0 | $1 | $1 | $1 |
| % Margin | 6.8% | 20.6% | 30.9% | 46.1% |
| R&D Expenses | $9 | $14 | $15 | $10 |
| G&A Expenses | $20 | $43 | $13 | $8 |
| SG&A Expenses | $20 | $43 | $13 | $8 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $1 | $31 | $15 |
| Operating Expenses | $29 | $43 | $58 | $33 |
| Operating Income | -$30 | -$42 | -$57 | -$33 |
| % Margin | -1,293.5% | -1,244.6% | -1,931.7% | -2,187.2% |
| Other Income/Exp. Net | -$4 | -$3 | $12 | -$2 |
| Pre-Tax Income | -$33 | -$46 | -$45 | -$36 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$33 | -$46 | -$45 | -$35 |
| % Margin | -1,461.6% | -1,340.2% | -1,524.4% | -2,329% |
| EPS | -0.62 | -1.1 | -1.24 | -0.98 |
| % Growth | 43.6% | 11.3% | -26.5% | – |
| EPS Diluted | -0.62 | -1.1 | -1.34 | -0.98 |
| Weighted Avg Shares Out | 54 | 41 | 34 | 35 |
| Weighted Avg Shares Out Dil | 54 | 41 | 37 | 36 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $1 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $1 | $0 | $0 |
| EBITDA | -$29 | -$42 | -$53 | -$36 |
| % Margin | -1,246% | -1,225.8% | -1,774.2% | -2,381.2% |